Moomoo AI 已提取核心訊息
On December 31, 2023, Tang Capital Partners, LP, along with Tang Capital Management, LLC, and Kevin Tang, collectively reported a shared voting and dispositive power over 2,750,000 shares of Altimmune, Inc.'s common stock, representing 5.1% of the company's class. This amendment was disclosed in a Schedule 13G/A filing with the Securities and Exchange Commission. The shares are beneficially owned by the reporting entities and person, with the percentages based on 53,728,871 shares of common stock outstanding as reported in Altimmune's Quarterly Report on November 3, 2023. The filing indicates that the ownership does not aim to change or influence the control of Altimmune, Inc. The information was certified as true and correct by Kevin Tang, Manager of Tang Capital Management, LLC, on February 14, 2024.
On December 31, 2023, Tang Capital Partners, LP, along with Tang Capital Management, LLC, and Kevin Tang, collectively reported a shared voting and dispositive power over 2,750,000 shares of Altimmune, Inc.'s common stock, representing 5.1% of the company's class. This amendment was disclosed in a Schedule 13G/A filing with the Securities and Exchange Commission. The shares are beneficially owned by the reporting entities and person, with the percentages based on 53,728,871 shares of common stock outstanding as reported in Altimmune's Quarterly Report on November 3, 2023. The filing indicates that the ownership does not aim to change or influence the control of Altimmune, Inc. The information was certified as true and correct by Kevin Tang, Manager of Tang Capital Management, LLC, on February 14, 2024.
2023年12月31日，唐資本合夥人有限責任公司以及唐資本管理有限責任公司和唐凱文共同報告了對Altimmune, Inc.275萬股股票的共同投票權和處置權。s 普通股，佔公司同類股的 5.1%。該修正案在向美國證券交易委員會提交的附表13G/A文件中披露。這些股票由申報實體和個人實益持有，百分比基於Altimmune在2023年11月3日發佈的季度報告中公佈的53,728,871股已發行普通股。該文件表明，該所有權的目的不是改變或影響Altimmune, Inc.的控制權。唐資本管理有限責任公司經理Kevin Tang於2024年2月14日認證該信息是真實和正確的。
2023年12月31日，唐資本合夥人有限責任公司以及唐資本管理有限責任公司和唐凱文共同報告了對Altimmune, Inc.275萬股股票的共同投票權和處置權。s 普通股，佔公司同類股的 5.1%。該修正案在向美國證券交易委員會提交的附表13G/A文件中披露。這些股票由申報實體和個人實益持有，百分比基於Altimmune在2023年11月3日發佈的季度報告中公佈的53,728,871股已發行普通股。該文件表明，該所有權的目的不是改變或影響Altimmune, Inc.的控制權。唐資本管理有限責任公司經理Kevin Tang於2024年2月14日認證該信息是真實和正確的。
有用
沒用